Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07. Submission of Matters to a Vote of Security Holders.

At the Special Meeting of Stockholders of Merrimack
Pharmaceuticals, Inc. (the Company) held on March30, 2017, the
Companys stockholders voted as follows:

1. The stockholders approved the Asset Sale to the terms of the
Asset Purchase and Sale Agreement, dated January7, 2017, by and
between the Company and Ipsen S.A.

2. The stockholders approved adoption of any proposal to adjourn
the Special Meeting to a later date or dates, if necessary or
appropriate, to solicit additional proxies if there were
insufficient votes to approve the Asset Sale at the time of the
Special Meeting.

About Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Recent Trading Information

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) closed its last trading session up +0.01 at 3.05 with 1,964,040 shares trading hands.